Immunosuppressive Medications in Kidney Transplantation

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 1134-1141

  Womer, Karl ^a   Rabb, Hamid ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959789503     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00097-6     Document Type: Chapter

References (12)

1. Samaniego M, Becker BN, Djamali A Drug insight: Maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol 2006, 2:688-699.
2. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996, 80(pt 2):S40-S45.
3. Schiff J, Cole E, Cantarovich M Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007, 2:374-384.
4. Jeong H, Kaplan B Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007, 2:184-191.
5. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007, 7:1822-1831.
6. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004, 4:237-243.
7. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231-236.
8. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant. 2007, 22(Suppl 8):viii61-viii65.
9. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997, 350:1193-1198.
10. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161-165.
11. Salama AD, Pusey CD Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006, 2:221-230.
12. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.